Oncology Reports.,2016, 36(2): 779-86
Publications
ChemPartner is a science-based, technology-driven global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO).
Identification of Novel EZH2 Inhibitors through Pharmacophore-based Virtual Screening and Biological Assays
Bioorganic & Medicinal Chemistry Letters. 2016, 26, 3813–3817
Identification of Novel Disruptor of Telomeric Silencing 1-Like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays
J. Chem. Inf. Model. 2016, 56 (3), 527–534
Design and Discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 Inhibitor
Bioorg Med Chem Lett. 2016, 26(3), 721-725
Discovery of novel inhibitors targeting menin-mixed lineage leukemia (MLL) interface using pharmacophore- and docking-based virtual screening
Journal of Chemical Information and Modeling. ahead of print
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window
J. Med. Chem., 2016, 59 (11), 5520–5541.
Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide
Bioorganic & Medicinal Chemistry Letters 26 (2016) 3182–3186
Fragment-Based Drug Discovery of 2‑Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization
J. Med. Chem. 2015, 58, 1281−1297
Headquarters
1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203
Contact Us
China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000